Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AGIO Agios Pharmaceuticals

Trading 06-05 10:11:30 EDT

28.90

+0.11

+0.38%

High29.39	Low28.72	Vol33.26K
Open28.95	D1 Closing28.79	Amplitude2.33%
Mkt Cap1.72B	Tradable Cap1.46B	Total Shares59.47M
T/O963.74K	T/O Rate0.07%	Tradable Shares50.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals","latestPrice":28.9,"timestamp":1780668683554,"preClose":28.79,"halted":0,"volume":33258,"delay":0,"changeRate":0.003820771101076743,"floatShares":50618600,"shares":59471609,"eps":-7.255931,"marketStatus":"Trading","change":0.11,"latestTime":"06-05 10:11:30 EDT","open":28.95,"high":29.39,"low":28.72,"amount":963736.52193,"amplitude":0.023272,"askPrice":28.89,"askSize":400,"bidPrice":28.77,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-7.255931,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780689600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":28.79,"preHourTrading":{"tag":"盘前","latestPrice":29.99,"preClose":28.79,"latestTime":"08:39 EDT","volume":9,"amount":265.550004,"timestamp":1780663144223,"change":1.2,"changeRate":0.041681,"amplitude":0.069121},"postHourTrading":{"tag":"盘后","latestPrice":28.79,"preClose":28.79,"latestTime":"17:25 EDT","volume":29451,"amount":847892.05,"timestamp":1780608323581,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.327359,"impliedVol":0.327,"impliedVolPercentile":0.0159},"requestUrl":"/m/hq/s/AGIO/tweets","defaultTab":"tweets","newsList":[{"id":"2640953136","title":"Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640953136","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640953136?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:31","pubTimestamp":1780309879,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293070","title":"Agios posts investor deck on cevidoplenib licensing deal in immune thrombocytopenia (ITP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640293070?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:56","pubTimestamp":1780307775,"startTime":"0","endTime":"0","summary":"Agios licensed cevidoplenib, a next-generation SYK inhibitor, expanding into immune thrombocytopenia, an estimated $3 billion-plus global market by 2030.Deal terms include a USD 25 million upfront payment, up to USD 140 million in development and regulatory milestones, tiered royalties from high single digits to mid-teens.Management pegged the U.S. commercial opportunity at up to USD 1 billion in peak annual sales, targeting about 24,000 refractory patients.Phase 2 met a key durability endpoint: 50% achieved at least two consecutive platelet counts ≥30,000/L vs 8.3% on placebo .Phase 3 is planned for the first half of 2028, with FY 2026 OpEx expected to be roughly flat vs FY 2025 excluding the upfront payment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4yq7C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640374029","title":"Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640374029","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640374029?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:13","pubTimestamp":1780305215,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) announced an agreement with Oscotec, headquartered in South Korea, to license the exclusive global rights to cevidople...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-enters-license-pact-with-oscotec-to-develop-cevidoplenib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-enters-license-pact-with-oscotec-to-develop-cevidoplenib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293788","title":"Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293788","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640293788?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:01","pubTimestamp":1780304464,"startTime":"0","endTime":"0","summary":"Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment. Agios signed an exclusive global license deal with Oscotec for cevidoplenib, a late-stage oral SYK inhibitor.Deal adds an immune thrombocytopenia program; Agios targets up to USD 1 billion in peak U.S. sales potential.Oscotec gets USD 25 million upfront; eligible for up to USD 140 million in development and regulatory milestones.Agreement includes commercial milestones; tiered royalties from high single digits to mid-teens on net sales.Oscotec can seek exclusive South Korea rights after Phase 3 results; Agios plans Phase 3 start in H1 2028.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL7tvzsX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014021.USD","BK4112","BK4588","NDAQ","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","LU2210150020.SGD","BK4585","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640932709","title":"Agios Pharmaceuticals - Oscotec to Receive $25 Mln Upfront Plus Milestone Payments and Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2640932709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640932709?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA728G4N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640932703","title":"Agios Pharmaceuticals - Oscotec Eligible for up to $140 Mln in Development and Regulatory Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2640932703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640932703?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA728G4N:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640693270","title":"Agios Pharmaceuticals - Oscotec Retains Option for Exclusive Rights to Cevidoplenib in South Korea","url":"https://stock-news.laohu8.com/highlight/detail?id=2640693270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640693270?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA728G4N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640327089","title":"Agios Pharmaceuticals - Expects 2026 Operating Expense Guidance to Be Flat Compared to 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2640327089","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640327089?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA728G4N:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640322629","title":"Agios Enters Exclusive Global License Agreement With Oscotec to Develop and Commercialize Next-Generation Syk Inhibitor Cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640322629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640322629?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA728G4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639674395","title":"Agios Pharmaceuticals Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2639674395","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639674395?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:30","pubTimestamp":1780079400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 14:30 ET (18:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639679743","title":"Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639679743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639679743?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:40","pubTimestamp":1780072811,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Becton Dickinson (BDX), Agios Pharma (AGIO) and He...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-becton-dickinson-bdx-agios-pharma-agio-and-healthequity-hqy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-becton-dickinson-bdx-agios-pharma-agio-and-healthequity-hqy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1854104046.USD","LU1854103824.USD","IE00BFXG1179.USD","LU0289739343.SGD","LABU","LU0068578508.USD","BDX","LU0433182093.SGD","LU1150488135.SGD","LU2095319765.USD","LU0072461881.USD","LU2210149790.SGD","HCSG","BK4504","BK4139","BK4581","BK4588","BK4585","BK4137","LU0477156797.USD","LU0130103400.USD","LU1571399168.USD","LU0130518102.USD","LU1059921491.USD","LU0029874061.USD","LU0985489474.SGD","XBI","XLV","AGIO","LU0878866978.SGD","LU1201861165.SGD","LU0162691827.USD","LU1489326972.SGD","LU0128526141.USD","LU0006061336.USD","LU1150488218.USD","BK4082","LU0511384066.AUD","LU2210150020.SGD","LU1169590202.USD","LU1894683348.USD","LU0289961442.SGD","LU1169589451.USD","LU0985320562.USD","LU2065731478.USD","LU0648000940.SGD","BK4154","HQY","LU1894683264.USD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676217","title":"Agios Pharmaceuticals price target lowered to $40 from $41 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639676217?lang=en_us&edition=fundamental","pubTime":"2026-05-29 23:28","pubTimestamp":1780068523,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $40 from $41 and keeps a Buy rating on the shares after the company announc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-lowered-to-40-from-41-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-lowered-to-40-from-41-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639620012","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune","url":"https://stock-news.laohu8.com/highlight/detail?id=2639620012","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639620012?lang=en_us&edition=fundamental","pubTime":"2026-05-29 21:21","pubTimestamp":1780060878,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, ReplimuneWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslett","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL6N4260OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4121","KRMN","LU1496350502.SGD","LU0265550359.USD","LU0417517546.SGD","LU2125909593.SGD","LU1066051811.HKD","LU1046421795.USD","GAP","LU2381873111.SGD","BK4596","BK4139","RKLB","LU0052756011.USD","BK4613","LU0823434583.USD","DLLL","LU2168564222.USD","IE00B5TLWC47.USD","BK4123","LU2237438978.USD","BK4550","LU0820561818.USD","LU0265550946.USD","LU0251142724.SGD","IFF","BK4602","COTG","BK4504","LU1323610961.USD","LU2065170008.USD","LU1066051225.USD","LU1923622614.USD","LU0471298694.HKD","UFO","LU1069344957.HKD","LU1066051498.USD","HK0000819398.USD","BK4094","BK4611","LU2065171311.SGD","LU1551013425.SGD","FLY","LU1861558580.USD","LU0820561909.HKD","PL","BK4515","LU0471298777.SGD","LU1551013342.USD","LU2433249047.HKD","LU1506573853.SGD","BK4585","LU0211326755.USD","LU1861559042.SGD","LU1066053197.SGD","BK4543","LU0943347566.SGD","LUNL","LU0496365809.HKD","FLYT","LU0234570918.USD","BK4187","REPL","LU2168564495.EUR","IE00BKVL7J92.USD","COST","LU2360032135.SGD","LU0310800965.SGD","BK4533","BK4588","BK4581","BK4561","LU0823434740.USD","BK4129","LU0976567544.SGD","LU0742534661.SGD","BK4615","AEO","IE00BZ1G4Q59.USD","LU0211326839.USD","MWH","TEMT","LU0079474960.USD","LU1235294995.USD","LU0251131958.USD","LU2360106947.USD","LU0128525689.USD","LU1116320737.USD","RKLZ","LU0689472784.USD","LU0985320562.USD","LU2210150020.SGD","PLU","LU0256863811.USD","LU1496350171.SGD","LU1035775433.USD","IE0008368304.USD","LU2125909247.SGD","LU2210149790.SGD","BK4564","LU0238689110.USD","BK4535","LU2168564065.EUR","LU2095319765.USD","LU0267386448.USD","TEM","LU2065171402.SGD","LU2065169927.USD","LU0234572021.USD","LU0048573561.USD","COSW","LU1571399168.USD","LU2168563687.JPY","BK4109","LU1267930227.SGD","BK4182","BK4170","LU2125154935.USD","LU1116320901.HKD","LU0314106906.USD","LU2168564149.EUR","LU0385154629.USD","BK4155","FPS","RKLX","LU2125154778.USD","LU1823568750.SGD","LU2097829019.USD","DELL","LUNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639762712","title":"BRIEF-Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2639762712","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639762712?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:32","pubTimestamp":1780057976,"startTime":"0","endTime":"0","summary":"BRIEF-Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic SyndromesMay 29 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:AGIOS PROVIDES UPDATE ON PHASE 2B TRIAL OF TEBAPIV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nTUA7F3TVS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639362408","title":"BUZZ-U.S. STOCKS ON THE MOVE-Costco, Firefly Aerospace, Agios","url":"https://stock-news.laohu8.com/highlight/detail?id=2639362408","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639362408?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:39","pubTimestamp":1780054763,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Costco, Firefly Aerospace, AgiosWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL6N4260PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLU","LU2065169927.USD","LU2125154935.USD","LU2125909247.SGD","LU1046421795.USD","LU0128525689.USD","BK4550","AEO","IE00B5TLWC47.USD","BK4588","LU0496365809.HKD","LU1823568750.SGD","LU1496350171.SGD","LU1066051811.HKD","COTG","LU0820561818.USD","LUNR","AGIO","FLYT","LU0079474960.USD","BK4155","LU0256863811.USD","LU2065171402.SGD","IE0008368304.USD","KRMN","DLLL","LU2360032135.SGD","BK4533","LU1116320901.HKD","LU2097829019.USD","UFO","LU2381873111.SGD","BK4515","LU0823434583.USD","IE00BZ1G4Q59.USD","COST","RKLZ","LU0211326839.USD","LU0265550359.USD","LU0471298777.SGD","BK4596","GAP","LU0689472784.USD","BK4094","LU2168563687.JPY","LU2095319765.USD","LU2168564495.EUR","LU2125154778.USD","LU0976567544.SGD","LU1267930227.SGD","BK4581","BK4585","LU0265550946.USD","LU0234570918.USD","BK4139","PL","BK4602","HK0000819398.USD","LU0385154629.USD","LU2210149790.SGD","LUNL","LU1069344957.HKD","LU1551013425.SGD","FLY","RKLB","LU2168564222.USD","LU0943347566.SGD","LU0820561909.HKD","DELL","LU2065171311.SGD","IE00BKVL7J92.USD","BK4504","LU2433249047.HKD","LU2168564149.EUR","LU1496350502.SGD","LU0417517546.SGD","BK4123","LU1551013342.USD","LU2360106947.USD","LU0211326755.USD","LU1066051498.USD","LU2237438978.USD","LU1116320737.USD","LU0238689110.USD","LU1066051225.USD","LU2210150020.SGD","BK4564","LU0267386448.USD","LU2168564065.EUR","LU1923622614.USD","LU1066053197.SGD","RKLX","LU0471298694.HKD","BK4170","LU1235294995.USD","COSW","LU1323610961.USD","BK4543","LU1035775433.USD","LU0234572021.USD","LU2125909593.SGD","LU0052756011.USD","LU0823434740.USD","LU2065170008.USD","BK4187","LU1571399168.USD","BK4535","BK4615","LU0310800965.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639242486","title":"Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2639242486","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639242486?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:30","pubTimestamp":1780054200,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals said it won't advance its tebapivat, an oral pyruvate kinase activator, in lower-risk myelodysplastic syndromes, after a Phase 2b trial didn't meet the company's predefined threshold to support further development in this indication.The commercial-stage biopharmaceutical company said the 24-week dose-finding trial evaluated once-daily tebapivat in 65 patients with LR-MDS and anemia.The primary endpoint was transfusion independence, defined as eight consecutive weeks without a transfusion during the 24-week treatment period. Agios said tebapivat demonstrated evidence of biological activity, but that it didn't see clinical benefit in a sufficient proportion of patients or subgroup of patients to meet the company's predefined threshold for advancement.Tebapivat was well tolerated across all dose levels, with no new safety signals identified.Agios said tebapivat is also being evaluated in a Phase 2 trial for the treatment of sickle cell disease, with top-line data ant","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639162624","title":"Agios Halts Development of Tebapivat in Lower-Risk MDS After Mid-Stage Trial Miss; Shares Drop Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2639162624","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639162624?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:27","pubTimestamp":1780054063,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  is set to discontinue development of tebapivat for lower-risk myelodysplastic syndromes after a phase 2b study failed to meet the company's threshold for further advancement, the company said on Friday.The open-label trial evaluated three dose levels of the oral pyruvate kinase activator in 65 patients with lower-risk MDS and anemia, it said. The primary endpoint measured transfusion independence over eight consecutive weeks during a 24-week treatment period, it added.Agios said tebapivat showed biological activity and was well tolerated, with no new safety concerns identified. However, the company said clinical benefit was not observed in enough patients to justify continued development in the indication, it added.Shares of Agios more down more than 6% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SSI","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639624969","title":"Agios will not advance tebapivat in lower-risk myelodysplastic syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2639624969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639624969?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:08","pubTimestamp":1780052897,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) announced that it will not advance tebapivat, a next-generation oral pyruvate kinase activator, in lower-risk myelodys...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-will-not-advance-tebapivat-in-lower-risk-myelodysplastic-syndromes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-will-not-advance-tebapivat-in-lower-risk-myelodysplastic-syndromes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639662101","title":"Agios Pharmaceuticals Shares Fall 19% Premarket After Co to Stop Development of Its Blood Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2639662101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639662101?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:07","pubTimestamp":1780052835,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4N426105:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639621098","title":"Agios scraps blood disorder drug program after study miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621098","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639621098?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:05","pubTimestamp":1780052715,"startTime":"0","endTime":"0","summary":"Agios scraps blood disorder drug program after study missMay 29 (Reuters) - Agios Pharmaceuticals AGIO.O said on Friday it will stop developing its experimental drug for a form of blood cancer after a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4N4260ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":-0.0536},{"period":"1month","weight":0.0581},{"period":"3month","weight":0.0481},{"period":"6month","weight":0.0382},{"period":"1year","weight":-0.154},{"period":"ytd","weight":0.0577}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.046},{"period":"3month","weight":0.126},{"period":"6month","weight":0.1041},{"period":"1year","weight":0.2704},{"period":"ytd","weight":0.1102}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.846154,"avgChangeRate":0.040392},{"month":2,"riseRate":0.692308,"avgChangeRate":0.060535},{"month":3,"riseRate":0.538462,"avgChangeRate":-0.001595},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.007034},{"month":5,"riseRate":0.615385,"avgChangeRate":0.052079},{"month":6,"riseRate":0.615385,"avgChangeRate":0.040713},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.012275},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.041451},{"month":9,"riseRate":0.538462,"avgChangeRate":0.042929},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.007074},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033339},{"month":12,"riseRate":0.384615,"avgChangeRate":-0.051358}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agios Pharmaceuticals,AGIO,Agios Pharmaceuticals股票,Agios Pharmaceuticals股票老虎,Agios Pharmaceuticals股票老虎国际,Agios Pharmaceuticals行情,Agios Pharmaceuticals股票行情,Agios Pharmaceuticals股价,Agios Pharmaceuticals股市,Agios Pharmaceuticals股票价格,Agios Pharmaceuticals股票交易,Agios Pharmaceuticals股票购买,Agios Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction